FMR LLC - ULTRAGENYX PHARMACEUTICAL IN ownership

ULTRAGENYX PHARMACEUTICAL IN's ticker is RARE and the CUSIP is 90400D108. A total of 219 filers reported holding ULTRAGENYX PHARMACEUTICAL IN in Q3 2023. The put-call ratio across all filers is 0.74 and the average weighting 0.2%.

Quarter-by-quarter ownership
FMR LLC ownership history of ULTRAGENYX PHARMACEUTICAL IN
ValueSharesWeighting
Q3 2023$36,640,517
-4.6%
1,027,785
+23.4%
0.00%0.0%
Q2 2023$38,411,367
-52.3%
832,677
-58.5%
0.00%
-25.0%
Q1 2023$80,522,686
+61.1%
2,008,048
+86.1%
0.00%
-20.0%
Q4 2022$49,993,474
+23.2%
1,079,074
+10.1%
0.01%
+25.0%
Q3 2022$40,572,000
-41.3%
979,779
-15.4%
0.00%
-42.9%
Q2 2022$69,102,000
-24.2%
1,158,242
-7.7%
0.01%0.0%
Q1 2022$91,177,000
-16.0%
1,255,524
-2.8%
0.01%
-12.5%
Q4 2021$108,592,000
+3.7%
1,291,379
+11.2%
0.01%0.0%
Q3 2021$104,709,000
+25.6%
1,160,985
+32.7%
0.01%
+14.3%
Q2 2021$83,395,000
-16.5%
874,614
-0.3%
0.01%
-22.2%
Q1 2021$99,914,000
-32.6%
877,514
-18.1%
0.01%
-30.8%
Q4 2020$148,327,000
+54.2%
1,071,499
-8.4%
0.01%
+30.0%
Q3 2020$96,171,000
-14.7%
1,170,099
-18.9%
0.01%
-16.7%
Q2 2020$112,801,000
+43.0%
1,442,102
-18.8%
0.01%
+9.1%
Q1 2020$78,895,000
+1.3%
1,775,710
-2.6%
0.01%
+22.2%
Q4 2019$77,876,000
-12.6%
1,823,374
-12.5%
0.01%
-18.2%
Q3 2019$89,137,000
-38.7%
2,083,621
-9.1%
0.01%
-35.3%
Q2 2019$145,497,000
-16.7%
2,291,288
-9.0%
0.02%
-19.0%
Q1 2019$174,630,000
+36.3%
2,517,746
-14.6%
0.02%
+16.7%
Q4 2018$128,133,000
-49.6%
2,946,924
-11.4%
0.02%
-37.9%
Q3 2018$254,011,000
-4.5%
3,327,381
-3.8%
0.03%
-6.5%
Q2 2018$265,899,000
+32.2%
3,459,085
-12.3%
0.03%
+29.2%
Q1 2018$201,154,000
+19.1%
3,944,982
+8.3%
0.02%
+20.0%
Q4 2017$168,912,000
-13.3%
3,641,921
-0.4%
0.02%
-16.7%
Q3 2017$194,783,000
-17.6%
3,657,208
-3.9%
0.02%
-17.2%
Q2 2017$236,280,000
-43.0%
3,804,225
-37.7%
0.03%
-45.3%
Q1 2017$414,178,000
+0.1%
6,110,627
+3.9%
0.05%
-3.6%
Q4 2016$413,622,000
-1.4%
5,882,825
-0.5%
0.06%
-1.8%
Q3 2016$419,474,000
+46.7%
5,913,075
+1.1%
0.06%
+43.6%
Q2 2016$286,015,000
-22.7%
5,847,783
+0.1%
0.04%
-23.5%
Q1 2016$369,834,000
-43.4%
5,841,631
+0.3%
0.05%
-42.0%
Q4 2015$653,217,000
+16.9%
5,822,942
+0.4%
0.09%
+10.0%
Q3 2015$558,598,000
+1.4%
5,799,996
+7.8%
0.08%
+12.7%
Q2 2015$550,943,000
+66.4%
5,380,827
+0.9%
0.07%
+69.0%
Q1 2015$331,112,000
+57.8%
5,332,783
+11.5%
0.04%
+55.6%
Q4 2014$209,809,000
-19.3%
4,781,420
+4.1%
0.03%
-22.9%
Q3 2014$260,034,000
+108.8%
4,594,240
+1.9%
0.04%
+105.9%
Q2 2014$124,517,000
+46.3%
4,508,893
+25.2%
0.02%
+41.7%
Q1 2014$85,100,0003,600,4880.01%
Other shareholders
ULTRAGENYX PHARMACEUTICAL IN shareholders Q3 2023
NameSharesValueWeighting ↓
EcoR1 Capital, LLC 497,899$31,617,0003.20%
HIGHLINE CAPITAL MANAGEMENT, L.P. 390,453$24,794,0001.81%
First Light Asset Management, LLC 180,017$11,431,0001.59%
Rock Springs Capital Management LP 580,000$36,830,0001.33%
Capital Impact Advisors, LLC 36,165$2,244,0000.82%
SECTOR GAMMA AS 79,653$5,058,0000.81%
Verity Asset Management, Inc. 7,193$457,0000.51%
Opus Point Partners Management, LLC 5,064$322,0000.48%
Capital International Sarl 52,000$3,302,0000.46%
PACIFIC VIEW ASSET MANAGEMENT, LLC 6,216$394,0000.43%
View complete list of ULTRAGENYX PHARMACEUTICAL IN shareholders